Intravenous immunoglobulin for Guillain-Barré syndrome
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Guillain-Barré syndrome (GBS) is an acute, paralysing, inflammatory peripheral nerve disease. Intravenous immunoglobulin (IVIg) is beneficial in other autoimmune diseases. This is an update of a review first published in 2001 and previously updated in 2003, 2005, 2007, 2010 and 2012. Other Cochrane systematic reviews have shown that plasma exchange (PE) significantly hastens recovery in GBS compared with supportive treatment alone, and that corticosteroids alone are ineffective. OBJECTIVES: We had the following four objectives.1. To examine the efficacy of intravenous immunoglobulin (IVIg) in hastening recovery and reducing the long-term morbidity from Guillain-Barré syndrome (GBS).2. To determine the most efficacious dose of IVIg in hastening recovery and reducing the long-term morbidity from GBS.3. To compare the efficacy of IVIg and plasma exchange (PE) or immunoabsorption in hastening recovery and reducing the long-term morbidity from GBS.4. To compare the efficacy of IVIg added to PE with PE alone in hastening recovery and reducing the long-term morbidity from GBS. SEARCH METHODS: We searched the Cochrane Neuromuscular Disease Group Specialized Register (2 December 2013), CENTRAL (2013, Issue 12 in The Cochrane Library), MEDLINE (January 1966 to November 2013) and EMBASE (January 1980 to November 2013). We checked the bibliographies in reports of the randomised trials and contacted the authors and other experts in the field to identify additional published or unpublished data. SELECTION CRITERIA: Randomised and quasi-randomised trials of IVIg compared with no treatment, placebo treatment, PE, or other immunomodulatory treatments in children and adults with GBS of all degrees of severity. We also included trials in which IVIg was added to another treatment. DATA COLLECTION AND ANALYSIS: Two authors independently selected papers, extracted data and assessed quality. We collected data about adverse events from the included trials. MAIN RESULTS: Twelve trials were found to be eligible for inclusion in this review. Seven trials with a variable risk of bias compared IVIg with PE in 623 severely affected participants. In five trials with 536 participants for whom the outcome was available, the mean difference (MD) of change in a seven-grade disability scale after four weeks was not significantly different between the two treatments: MD of 0.02 of a grade more improvement in the intravenous immunoglobulin than the plasma exchange group; 95% confidence interval (CI) 0.25 to -0.20. There were also no statistically significant differences in the other measures considered. Three studies including a total of 75 children suggested that IVIg significantly hastens recovery compared with supportive care. The primary outcome for this review, available for only one trial with 21 mildly affected children, showed significantly more improvement in disability grade after four weeks with IVIg than supportive treatment alone, MD 1.42, 95% CI 2.57 to 0.27.In one trial involving 249 participants comparing PE followed by IVIg with PE alone, the mean grade improvement was 0.2 (95% CI -0.14 to 0.54) more in the combined treatment group than in the PE alone group; not clinically significantly different, but not excluding the possibility of significant extra benefit. Another trial with 34 participants comparing immunoabsorption followed by IVIg with immunoabsorption alone did not reveal significant extra benefit from the combined treatment.Adverse events were not significantly more frequent with either treatment, but IVIg is significantly much more likely to be completed than PE.Small trials in children showed a trend towards more improvement with high-dose compared with low-dose IVIg, and no significant difference when the standard dose was given over two days rather than five days. AUTHORS' CONCLUSIONS: A previous Cochrane review has shown that PE hastens recovery compared with supportive treatment alone. There are no adequate comparisons of IVIg with placebo in adults, but this review provides moderate quality evidence that, in severe disease, IVIg started within two weeks from onset hastens recovery as much as PE. Adverse events were not significantly more frequent with either treatment but IVIg is significantly much more likely to be completed than PE. Also, according to moderate quality evidence, giving IVIg after PE did not confer significant extra benefit. In children, according to low quality evidence, IVIg probably hastens recovery compared with supportive care alone. More research is needed in mild disease and in patients whose treatment starts more than two weeks after onset. Dose-ranging studies are also needed and one is in progress.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2008) · Cited by 3,790
Assessing Risk of Bias in Included Studies
Higgins, J. P., & Altman, D. G. (2008) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9780470712184.ch8 · Cited by 3,396
Assessment of current diagnostic criteria for Guillain-Barr� syndrome
Asbury, A. K., & Cornblath, D. R. (1990) · Annals of Neurology · doi:10.1002/ana.410270707 · Cited by 1,905
Hughes, R. A., & Cornblath, D. R. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67665-9 · Cited by 1,676
Self-citationHIGH-DOSE INTRAVENOUS GAMMAGLOBULIN FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA IN CHILDHOOD
Imbach, P., d'APUZZO, V., Hirt, A., Rossi, E., Vest, M., Barandun, S., Baumgartner, C., Morell, A., Schöni, M., & Wagner, H. P. (1981) · The Lancet · doi:10.1016/s0140-6736(81)92400-4 · Cited by 1,666
(2010) · Handbook of Disease Burdens and Quality of Life Measures · doi:10.1007/978-0-387-78665-0_6514 · Cited by 1,385
Yuki, N., & Hartung, H.-P. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1114525 · Cited by 1,260
Newburger, J. W., Takahashi, M., Beiser, A. S., Burns, J. C., Bastian, J., Chung, K. J., Colan, S. D., Duffy, C. E., Fulton, D. R., Glode, M. P., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199106063242305 · Cited by 1,220
van der Meché, F. G. A., Schmitz, P. I. M., & the Dutch Guillain–Barré Study Group* (1992) · New England Journal of Medicine · doi:10.1056/nejm199204233261705 · Cited by 1,143
Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion
Llewelyn, C., Hewitt, P., Knight, R., Amar, K., Cousens, S., Mackenzie, J., & Will, R. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15486-x · Cited by 1,128
CONTROLLED TRIAL OF PREDNISOLONE IN ACUTE POLYNEUROPATHY
Hughes, R. A. C., Newsom-Davis, J. M., Perkin, G. D., & Pierce, J. M. (1978) · The Lancet · doi:10.1016/s0140-6736(78)92644-2 · Cited by 1,123
Self-citationPublished by John Wiley & Sons Ltd
Modarresi, O. A. F., & Shakibaie, M. M. M. R. (2015) · Cited by 1,111
Electrophysiological classification of guillain‐barré syndrome: Clinical associations and outcome
Hadden, R. D. M., Cornblath, D. R., Hughes, R. A. C., Zielasek, J., Hartung, H. ‐., Toyka, K. V., Swan, A. V., & The Plasma Exchange/Sandoglobulin Guillain‐Barré Syndrome Trial Group (1998) · Annals of Neurology · doi:10.1002/ana.410440512 · Cited by 942
Self-citationKleyweg, R. P., Van Der Meché, F. G. A., & Schmitz, P. I. M. (1991) · Muscle & Nerve · doi:10.1002/mus.880141111 · Cited by 926
Merkies, I. S. J., & Kieseier, B. C. (2016) · European Neurology · doi:10.1159/000445347 · Cited by 869
Plasmapheresis and acute Guillain‐Barre syndrome
The Guillain-Barré Syndrome Study Group (1985) · Neurology · doi:10.1212/wnl.35.8.1096 · Cited by 773
(1997) · The Lancet · doi:10.1016/s0140-6736(96)09095-2 · Cited by 733
Meyler's Side Effects of Drugs
Breckenridge, A. M. (1976) · BMJ · doi:10.1136/bmj.2.6030.307 · Cited by 691
Sejvar, J. J., Kohl, K. S., Gidudu, J., Amato, A., Bakshi, N., Baxter, R., Burwen, D. R., Cornblath, D. R., Cleerbout, J., Edwards, K. M., et al. (2011) · Vaccine · doi:10.1016/j.vaccine.2010.06.003 · Cited by 652
Self-citation(1997) · Transfusion Medicine Reviews · doi:10.1016/s0887-7963(97)80059-4 · Cited by 610
Immunotherapy for Guillain-Barre syndrome: a systematic review
Hughes, R. A. C., Swan, A. V., Raphael, J.-C., Annane, D., van Koningsveld, R., & van Doorn, P. A. (2007) · Brain · doi:10.1093/brain/awm004 · Cited by 463
Self-citationEfficiency of plasma exchange in Guillain‐Barré syndrome: Role of replacement fluids
French Cooperative Group on Plasma Exchange in Guillain‐Barrk Syndrome (1987) · Annals of Neurology · doi:10.1002/ana.410220612 · Cited by 457
Mechanism of Intravenous Immune Globulin Therapy in Antibody-Mediated Autoimmune Diseases
Yu, Z., & Lennon, V. A. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901213400311 · Cited by 427
England, J. (1990) · Annual Review of Medicine · doi:10.1146/annurev.med.41.1.1 · Cited by 408
Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies
van Nes, S. I., Vanhoutte, E. K., van Doorn, P. A., Hermans, M., Bakkers, M., Kuitwaard, K., Faber, C. G., & Merkies, I. S. J. (2011) · Neurology · doi:10.1212/wnl.0b013e318208824b · Cited by 381
Self-citationCampylobacter jejuni infections and anti‐GM1 antibodies in guillain‐barré syndrome
Jacobs, B. C., van Doorn, P. A., Tio‐Gillen, A. P., Visser, L. H., van der Meché, F. G. A., Schmitz, P. I. M., Herbrink, P., & Hooijkaas, H. (1996) · Annals of Neurology · doi:10.1002/ana.410400209 · Cited by 314
Self-citationFatigue in immune-mediated polyneuropathies
Merkies, I. S. J., Schmitz, P. I. M., Samijn, J. P. A., van der Meché, F. G. A., & van Doorn, P. A. (1999) · Neurology · doi:10.1212/wnl.53.8.1648 · Cited by 277
Self-citationAppropriate number of plasma exchanges in Guillain‐Barré syndrome
The French Cooperative Group on Plasma Exchange in Guillain‐Barré Syndrome (1997) · Annals of Neurology · doi:10.1002/ana.410410304 · Cited by 261
Epidemiological study of Guillain-Barre syndrome in south east England
Rees, J. H., Thompson, R. D., Smeeton, N. C., & Hughes, R. A. C. (1998) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.64.1.74 · Cited by 258
Self-citationOutcome and its predictors in Guillain–Barré syndrome
Rajabally, Y. A., & Uncini, A. (2012) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2011-301882 · Cited by 246
Tackenberg, B., Jelčić, I., Baerenwaldt, A., Oertel, W. H., Sommer, N., Nimmerjahn, F., & Lünemann, J. D. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807319106 · Cited by 242
Treatment of Guillain‐Barré syndrome with high‐dose gammaglobulin
Kleyweg, R. P., van der Meché, F. G. A., & Meulstee, J. (1988) · Neurology · doi:10.1212/wnl.38.10.1639 · Cited by 233
Hughes, R. A., Raphael, J., Swan, A. V., & van Doorn, P. A. (2001) · Research Portal (King's College London) · Cited by 220
Self-citationDalakas, M. C. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.04.002 · Cited by 217
Korinthenberg, R., Schessl, J., Kirschner, J., & Mönting, J. S. (2005) · PEDIATRICS · doi:10.1542/peds.2004-1324 · Cited by 186
Plasma and gamma-globulin infusion in chronic inflammatory polyneuropathy
Vermeulen, M., van der Meché, F. G. A., Speelman, J. D., Weber, A., & Busch, H. F. M. (1985) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(85)90173-x · Cited by 178
CONTROLLED TRIAL OF PLASMA EXCHANGE IN ACUTE INFLAMMATORY POLYRADICULONEUROPATHY
Greenwood, R. J., Hughes, R. A. C., Bowden, A. N., Gordon, N. S., Millac, P., Newsom-Davis, J., Aslan, S., Chadwick, D. W., Mclellan, D. L., Stott, R. B., et al. (1984) · The Lancet · doi:10.1016/s0140-6736(84)91341-2 · Cited by 169
Self-citationTyrosine metabolism and faecal amino-acids in cystic fibrosis of the pancreas.
Gibbons, I. S. E., Seakins, J. W. T., & Ersser, R. S. (1967) · The Lancet · Cited by 161
Plasma exchange in Guillain‐Barré syndrome: One‐year follow‐up
French Cooperative Group on Plasma Exchange in Guillain‐Barré Syndrome (1992) · Annals of Neurology · doi:10.1002/ana.410320115 · Cited by 154
Acute Renal Failure Resulting From Intravenous Immunoglobulin Therapy
Tan, E., Hajinazarian, M., Bay, W. H., Neff, J., & Mendell, J. R. (1993) · Archives of Neurology · doi:10.1001/archneur.1993.00540020015010 · Cited by 149
Plasmapheresis and acute Guillain-Barré syndrome. The Guillain-Barré syndrome Study Group.
(1985) · PubMed · Cited by 116
Intravenous Immunoglobulin Treatment in Children with Guillain-Barre Syndrome
Gürses, N., Uysal, S., Çetinkaya, F., Işek, I., & Kalaycı, A. G. (1995) · Scandinavian Journal of Infectious Diseases · doi:10.3109/00365549509019016 · Cited by 102
El‐Bayoumi, M. A., El-Refaey, A. M., AbdelKader, A. M., El‐Assmy, M., Alwakeel, A. A., & El-Tahan, H. M. (2011) · Critical Care · doi:10.1186/cc10305 · Cited by 102
Nephrotoxicity of intravenous immunoglobulin
Levy, J. B. (2000) · QJM · doi:10.1093/qjmed/93.11.751 · Cited by 85
Intravenous immunoglobulin therapy for Guillain-Barr� syndrome with IgG anti-GM1 antibody
Kuwabara, S., Mori, M., Ogawara, K., Hattori, T., Oda, S., Koga, M., & Yuki, N. (2001) · Muscle & Nerve · doi:10.1002/1097-4598(200101)24:1<54::aid-mus6>3.0.co;2-9 · Cited by 75
Intravenous immunoglobulin for Guillain-Barré syndrome
Hughes, R. A. C., Raphaël, J. C., Swan, A. V., & van Doorn, P. A. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002063.pub2 · Cited by 68
Self-citationIntravenous immunoglobulin treatment in children with Guillain-Barré syndrome
Kanra, G., Ozon, A., Vajsar, J., Castagna, L., Secmeer, G., & Topaloğlu, H. (1997) · European Journal of Paediatric Neurology · doi:10.1016/s1090-3798(97)80004-9 · Cited by 67
Haupt, W. F., Rosenow, F., van der Ven, C., Borberg, H., & Pawlik, G. (1996) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(95)00357-8 · Cited by 49
Update on Guillain‐Barré syndrome
Rinaldi, S. (2013) · Journal of the Peripheral Nervous System · doi:10.1111/jns5.12020 · Cited by 45
Apheresis and Selective Adsorption Plus Immunoglobulin Treatment in Guillain‐Barré Syndrome
Haupt, W. F., Birkmann, C., van der Ven, C., & Pawlik, G. (2000) · Therapeutic Apheresis and Dialysis · doi:10.1046/j.1526-0968.2000.00182.x · Cited by 25
Haupt, W. F., Rosenow, F., van der Ven, C., Borberg, H., & Pawlik, G. (1997) · Therapeutic Apheresis and Dialysis · doi:10.1111/j.1744-9987.1997.tb00014.x · Cited by 13
Blood, blood components, plasma and plasma products
Eijkhout, H. W., & van Aken, W. G. (1993) · Side effects of drugs annual · doi:10.1016/s0378-6080(05)80218-1 · Cited by 11
Schlenke, P., & Sibrowski, W. (2009) · Transfusion Medicine and Hemotherapy · doi:10.1159/000268065 · Cited by 5
Cann, S. A. H., Netten, J. P. V., & Netten, C. V. (2000) · Pure Amsterdam UMC · doi:10.1002/1531-8249(200003)47:3
Cited by
Padmanabhan, A., Connelly‐Smith, L., Aqui, N., Balogun, R. A., Klingel, R., Meyer, E., Pham, H. P., Schneiderman, J., Witt, V., Wu, Y., et al. (2019) · Journal of Clinical Apheresis · doi:10.1002/jca.21705 · Cited by 2,230
Hughes, R. A., & Cornblath, D. R. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67665-9 · Cited by 1,676
Self-citationWillison, H. J., Jacobs, B. C., & van Doorn, P. A. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00339-1 · Cited by 1,609
Self-citationGuillain–Barré syndrome: pathogenesis, diagnosis, treatment and prognosis
van den Berg, B., Walgaard, C., Drenthen, J., Fokke, C., Jacobs, B. C., & van Doorn, P. A. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.121 · Cited by 1,101
Self-citationDiagnosis and management of Guillain–Barré syndrome in ten steps
Leonhard, S. E., Mandarakas, M. R., Gondim, F. A. A., Bateman, K., Ferreira, M. L. B., Cornblath, D. R., van Doorn, P. A., Dourado, M. E., Hughes, R. A. C., Islam, B., et al. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0250-9 · Cited by 910
Self-citation
Metadata
- Authors
- Hughes, R. A., Swan, A. V., & van Doorn, P. A.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2014-09-19
- Volume
- 2019
- Issue
- 10
- Pages
- CD002063-CD002063
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1940461546
- Cited by
- 721
- References
- 55
- FWCI
- 30.27
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.